{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Gadopentetate+dimeglumine", "query": { "intervention": "Gadopentetate dimeglumine" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 63, "total_pages": 7, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Gadopentetate+dimeglumine&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-09-29T05:51:42.681Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT01989195", "title": "Efficacy of EVP 1001-1 (SeeMore) in the Assessment of Myocardial Viability in Patients With Cardiovascular Disease", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "ISCHEMIC CARDIOMYOPATHY" ], "interventions": [ { "name": "'SEEMORE' - MANGANESE-ENHANCED MRI CONTRAST REAGENT", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Stanford University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "70 Years", "sex": "ALL", "summary": "18 Years to 70 Years" }, "enrollment_count": 6, "start_date": "2013-05", "completion_date": "2013-06", "has_results": true, "last_update_posted_date": "2017-01-02", "last_synced_at": "2026-09-29T05:51:42.681Z", "location_count": 1, "location_summary": "Stanford, California", "locations": [ { "city": "Stanford", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01989195" }, { "nct_id": "NCT02501759", "title": "Transrectal MRI-Guided Biopsy in Identifying Cancer in Patients With Suspected Prostate Cancer", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Health Status Unknown", "Prostate Carcinoma" ], "interventions": [ { "name": "3 Tesla Magnetic Resonance Imaging", "type": "PROCEDURE" }, { "name": "Gadodiamide", "type": "RADIATION" }, { "name": "Multiparametric Magnetic Resonance Imaging", "type": "PROCEDURE" }, { "name": "Transrectal Biopsy", "type": "PROCEDURE" }, { "name": "Ultrasound-Guided Prostate Biopsy", "type": "PROCEDURE" } ], "intervention_types": [ "PROCEDURE", "RADIATION" ], "sponsor": "OHSU Knight Cancer Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": null, "sex": "MALE", "summary": "Male only" }, "enrollment_count": 2, "start_date": "2015-05", "completion_date": "2017-02-10", "has_results": true, "last_update_posted_date": "2019-04-03", "last_synced_at": "2026-09-29T05:51:42.681Z", "location_count": 1, "location_summary": "Portland, Oregon", "locations": [ { "city": "Portland", "state": "Oregon" } ], "official_url": "https://clinicaltrials.gov/study/NCT02501759" }, { "nct_id": "NCT01988675", "title": "MRI Study of Radiation-Induced Damage to White Matter and Blood-Brain-Barrier", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Brain Neoplasms" ], "interventions": [ { "name": "Whole Brain Irradiation", "type": "RADIATION" }, { "name": "Partial Brain Irradiation", "type": "RADIATION" }, { "name": "Neuropsychological Testing", "type": "BEHAVIORAL" }, { "name": "Quality of Life Questionnaire", "type": "BEHAVIORAL" }, { "name": "Magnetic Resonance Imaging (MRI) Assessments", "type": "DEVICE" } ], "intervention_types": [ "RADIATION", "BEHAVIORAL", "DEVICE" ], "sponsor": "University of Michigan Rogel Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 91, "start_date": "2004-08-26", "completion_date": "2014-06-03", "has_results": false, "last_update_posted_date": "2018-06-06", "last_synced_at": "2026-09-29T05:51:42.681Z", "location_count": 1, "location_summary": "Ann Arbor, Michigan", "locations": [ { "city": "Ann Arbor", "state": "Michigan" } ], "official_url": "https://clinicaltrials.gov/study/NCT01988675" }, { "nct_id": "NCT01211873", "title": "Safety and Efficacy Evaluation of DOTAREM® in MRI of Central Nervous System (CNS) Lesions", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Diagnostic Self Evaluation", "Central Nervous System Diseases" ], "interventions": [ { "name": "Dotarem (gadoterate meglumine)", "type": "DRUG" }, { "name": "Magnevist (gadopentetate dimeglumine)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Guerbet", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "2 Years", "maximum_age": null, "sex": "ALL", "summary": "2 Years and older" }, "enrollment_count": 416, "start_date": "2010-09", "completion_date": "2011-11", "has_results": true, "last_update_posted_date": "2019-04-18", "last_synced_at": "2026-09-29T05:51:42.681Z", "location_count": 20, "location_summary": "Birmingham, Alabama • Tucson, Arizona • Indian Wells, California + 14 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Indian Wells", "state": "California" }, { "city": "Hollywood", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT01211873" }, { "nct_id": "NCT01996527", "title": "3T MRI Biomarkers of Glioma Treatment Response", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "EARLY_PHASE1" ], "conditions": [ "Adult Anaplastic Astrocytoma", "Adult Anaplastic Ependymoma", "Adult Anaplastic Oligodendroglioma", "Adult Giant Cell Glioblastoma", "Adult Glioblastoma", "Adult Gliosarcoma", "Recurrent Adult Brain Tumor" ], "interventions": [ { "name": "3-Tesla magnetic resonance imaging", "type": "DEVICE" }, { "name": "CEST-MRI", "type": "DEVICE" }, { "name": "DW-MRI", "type": "DEVICE" }, { "name": "DCE-MRI", "type": "DEVICE" }, { "name": "DSC-MRI", "type": "DEVICE" }, { "name": "IV administration of gadolinium-containing contrast agent", "type": "DRUG" } ], "intervention_types": [ "DEVICE", "DRUG" ], "sponsor": "Vanderbilt-Ingram Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 7, "start_date": "2012-05", "completion_date": "2016-01-01", "has_results": false, "last_update_posted_date": "2017-04-17", "last_synced_at": "2026-09-29T05:51:42.681Z", "location_count": 1, "location_summary": "Nashville, Tennessee", "locations": [ { "city": "Nashville", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT01996527" }, { "nct_id": "NCT02597543", "title": "Stress Cardiac MRI for Evaluation of Nonspecific Allograft Dysfunction", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Heart Transplant", "Acute Graft Rejection", "Chronic Graft Rejection" ], "interventions": [ { "name": "Regadenoson", "type": "DRUG" }, { "name": "Gadolinium", "type": "DRUG" }, { "name": "Cardiac MRI", "type": "PROCEDURE" } ], "intervention_types": [ "DRUG", "PROCEDURE" ], "sponsor": "Paul Kim", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 14, "start_date": "2015-11", "completion_date": "2016-06-30", "has_results": true, "last_update_posted_date": "2017-08-22", "last_synced_at": "2026-09-29T05:51:42.681Z", "location_count": 1, "location_summary": "La Jolla, California", "locations": [ { "city": "La Jolla", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02597543" }, { "nct_id": "NCT02123615", "title": "ASIS for GAMMAGARD in Primary Immunodeficiency", "overall_status": "UNKNOWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Primary Immunodeficiency" ], "interventions": [ { "name": "Gadolinium For abdomen", "type": "DRUG" }, { "name": "Gadolinium For lower back", "type": "DRUG" }, { "name": "Efficacy of Gammagard subcutaneously at Week 12", "type": "DRUG" }, { "name": "Efficacy of Gammagard subcutaneously at Week 24", "type": "DRUG" }, { "name": "Efficacy of Gammagard subcutaneously at Week 36", "type": "DRUG" }, { "name": "Efficacy of Gammagard subdermally at Week 36", "type": "DRUG" }, { "name": "Efficacy of Gammagard subdermally at Week 12", "type": "DRUG" }, { "name": "Efficacy of Gammagard subdermally at Week 24", "type": "DRUG" }, { "name": "Adverse Reactions of Gammagard subcutaneously at Week 12", "type": "DRUG" }, { "name": "Adverse Reactions of Gammagard subcutaneously at Week 24", "type": "DRUG" }, { "name": "Adverse Reactions of Gammagard subcutaneously at Week 36", "type": "DRUG" }, { "name": "Adverse Reactions of Gammagard subdermally at Week 12", "type": "DRUG" }, { "name": "Adverse Reactions of Gammagard subdermally at Week 24", "type": "DRUG" }, { "name": "Adverse Reactions of Gammagard subdermally at Week 36", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "ASIS Corporation", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "21 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "21 Years to 65 Years" }, "enrollment_count": 60, "start_date": "2016-01", "completion_date": "2016-06", "has_results": false, "last_update_posted_date": "2015-06-24", "last_synced_at": "2026-09-29T05:51:42.681Z", "location_count": 1, "location_summary": "Westminster, California", "locations": [ { "city": "Westminster", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02123615" }, { "nct_id": "NCT00744939", "title": "Risk of Nephrogenic Systemic Fibrosis (NSF) in Patients With Moderate Renal Insufficiency After the Administration of Magnevist", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Fibrosis", "Kidney Failure", "Renal Insufficiency" ], "interventions": [ { "name": "Gadopentetate dimeglumine (Magnevist, BAY86-4882)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Bayer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "2 Years", "maximum_age": null, "sex": "ALL", "summary": "2 Years and older" }, "enrollment_count": 168, "start_date": "2008-11", "completion_date": "2013-11", "has_results": true, "last_update_posted_date": "2014-09-22", "last_synced_at": "2026-09-29T05:51:42.681Z", "location_count": 26, "location_summary": "Phoenix, Arizona • Chula Vista, California • Los Angeles, California + 19 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Chula Vista", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Santa Rosa", "state": "California" }, { "city": "Pueblo", "state": "Colorado" } ], "official_url": "https://clinicaltrials.gov/study/NCT00744939" }, { "nct_id": "NCT02933034", "title": "Clinical Trial of Manganese-Enhanced MRI (MEMRI) to Assess Peri-Infarct Injury", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "ISCHEMIC CARDIOMYOPATHY" ], "interventions": [ { "name": "Manganese-enhanced MRI contrast reagent", "type": "DRUG" }, { "name": "Gadolinium-enhanced MRI contrast reagent", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Stanford University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "70 Years", "sex": "ALL", "summary": "18 Years to 70 Years" }, "enrollment_count": 33, "start_date": "2015-04", "completion_date": "2019-02-03", "has_results": true, "last_update_posted_date": "2020-02-17", "last_synced_at": "2026-09-29T05:51:42.681Z", "location_count": 1, "location_summary": "Stanford, California", "locations": [ { "city": "Stanford", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02933034" }, { "nct_id": "NCT02092428", "title": "Contrast- Enhanced Whole-Heart Coronary MRA at 3.0T (Tesla)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Coronary Artery Disease" ], "interventions": [ { "name": "Image Quality", "type": "OTHER" }, { "name": "Diagnostic Accuracy", "type": "OTHER" } ], "intervention_types": [ "OTHER" ], "sponsor": "Cedars-Sinai Medical Center", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 333, "start_date": "2011-04", "completion_date": "2017-03-01", "has_results": false, "last_update_posted_date": "2018-03-23", "last_synced_at": "2026-09-29T05:51:42.681Z", "location_count": 1, "location_summary": "Los Angeles, California", "locations": [ { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02092428" } ] }